Kura Oncology logo

Kura OncologyNASDAQ: KURA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 September 2015

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$785.41 M
-56%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 7 min ago
$10.10-$4.15(-29.12%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

KURA Latest News

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: POSITIVE

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
globenewswire.com24 October 2024 Sentiment: POSITIVE

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
globenewswire.com30 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial,” is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura's website.

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
globenewswire.com17 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership.

Kura Oncology to Report Second Quarter 2024 Financial Results
globenewswire.com01 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
globenewswire.com24 June 2024 Sentiment: POSITIVE

– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
businesswire.com11 June 2024 Sentiment: POSITIVE

SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Kura Oncology are continuing their partnership to support the San Diego community. Kura Oncology is contributing $100,000 through Life Science Cares' Basic Needs portfolio to support local nonprofit, Mama's Kitchen, with meeting.

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Seeking Alpha04 May 2024 Sentiment: POSITIVE

Kura Oncology, Inc. (NASDAQ:KURA) held its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present on the call were Pete De Spain, Troy Wilson, and Thomas Doyle from the company. Various analysts and investors also participated in the call. The operator welcomed all participants to the conference call, which was in listen-only mode.

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
GlobeNewsWire20 February 2024 Sentiment: NEGATIVE

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology stock jumped another 20% on Tuesday: here's why
Invezz30 January 2024 Sentiment: POSITIVE

Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial studied the combination in patients of acute myeloid leukemia.

What type of business is Kura Oncology?

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

What sector is Kura Oncology in?

Kura Oncology is in the Healthcare sector

What industry is Kura Oncology in?

Kura Oncology is in the Biotechnology industry

What country is Kura Oncology from?

Kura Oncology is headquartered in United States

When did Kura Oncology go public?

Kura Oncology initial public offering (IPO) was on 16 September 2015

What is Kura Oncology website?

https://kuraoncology.com

Is Kura Oncology in the S&P 500?

No, Kura Oncology is not included in the S&P 500 index

Is Kura Oncology in the NASDAQ 100?

No, Kura Oncology is not included in the NASDAQ 100 index

Is Kura Oncology in the Dow Jones?

No, Kura Oncology is not included in the Dow Jones index

When was Kura Oncology the previous earnings report?

No data

When does Kura Oncology earnings report?

The next expected earnings date for Kura Oncology is 27 February 2025